• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy
This study was designed to check the combined effect of CD133 siRNA and Oxaliplatin on proliferation, migration, apoptosis, and stemness properties of CRC cells in the HT-29 cell line. MTT assay was performed to define the combined effect of CD133 siRNA and Oxaliplatin on the viability of HT-29 cells, and it showed that the combination of CD133 siRNA and Oxaliplatin could reduce the IC50 of this drug from 32.85 to 19.75 nmol. In order to figure out the effect of this combination therapy on CD133 expression at the gene and protein level, qRT-PCR and western blot were exploited, respectively. The results demonstrated that th...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 16, 2021 Category: Drugs & Pharmacology Authors: Zahra Asadzadeh Behzad Mansoori Ali Mohammadi Tohid Kazemi Ahad Mokhtarzadeh Dariush Shanehbandi Nima Hemmat Afshin Derakhshani Oronzo Brunetti Sahar Safaei Marjan Aghajani Souzan Najafi Nicola Silvestris Behzad Baradaran Source Type: research

The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy.
This study was designed to check the combined effect of CD133 siRNA and Oxaliplatin on proliferation, migration, apoptosis, and stemness properties of CRC cells in the HT-29 cell line. MTT assay was performed to define the combined effect of CD133 siRNA and Oxaliplatin on the viability of HT-29 cells, and it showed that the combination of CD133 siRNA and Oxaliplatin could reduce the IC50 of this drug from 32.85 to 19.75 nmol. In order to figure out the effect of this combination therapy on CD133 expression at the gene and protein level, qRT-PCR and western blot were exploited, respectively. The results demonstrated that th...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 13, 2021 Category: Drugs & Pharmacology Authors: Asadzadeh Z, Mansoori B, Mohammadi A, Kazemi T, Mokhtarzadeh A, Shanehbandi D, Hemmat N, Derakhshani A, Brunetti O, Safaei S, Aghajani M, Najafi S, Silvestris N, Baradaran B Tags: Biomed Pharmacother Source Type: research

A Study on Effect of Oxaliplatin in MicroRNA Expression in Human Colon Cancer
This study outlines the regulatory effects of oxaliplatin on miRNAs expression in colon cancer cells and correlates it with the changing microRNA expression with p53 and p73 expression status in cells. HCT116p53+/+ and HCT116p53-/- cells were exposed to oxaliplatin, and the cellular viability was determined by XTT. p73 was knocked down using siRNA and the tumor cells were then treated with oxaliplatin. The expression profile of 384 miRNAs was determined by TaqMan® human miRNA array and calculated by the ∆∆Ct method. Cellular viability was found to decrease after the treatment with oxaliplatin in a dose-dep...
Source: Journal of Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Jasmine Evert, Surajit Pathak, Xiao-Feng Sun, Hong Zhang Tags: Research Paper Source Type: research

TRIB3 downregulation enhances doxorubicin-induced cytotoxicity in gastric cancer cells.
Abstract TRIB3, which is a pseudokinase known to regulate multiple pro-survival pathways, appears to be a potential therapeutic target for the treatment of human tumors. However, its precise role in cancer is controversial, as TRIB3 protein levels have been associated with both good and poor prognosis in cancer patients. Here, we investigated the significance of TRIB3 expression in the survival of gastric cancer cells exposed to anticancer drugs. We found that the tested anticancer drug, doxorubicin, induced cytotoxicity by decreasing TRIB3 transcription, which was followed by apoptotic cell death. Moreover, TRIB3...
Source: Archives of Biochemistry and Biophysics - April 22, 2017 Category: Biochemistry Authors: Wu IJ, Lin RJ, Wang HC, Yuan TM, Chuang SM Tags: Arch Biochem Biophys Source Type: research

Silencing the livin gene enhances the cytotoxic effects of anticancer drugs on colon cancer cells.
CONCLUSION: siRNA-mediated down-regulation of livin gene expression could significantly suppress colon cancer growth and enhance the cytotoxic effects of anticancer drugs such as 5-FU and L-OHP. The results of this study suggest that silencing livin gene expression in combination with treatment with anticancer drugs might be a novel cancer therapy for colorectal cancer. PMID: 27904848 [PubMed - in process]
Source: Annals of Surgical Treatment and Research - December 3, 2016 Category: Surgery Tags: Ann Surg Treat Res Source Type: research

Downregulation of SMC1A inhibits growth and increases apoptosis and chemosensitivity of colorectal cancer cells
Conclusions The findings of this study suggest that SMC1A plays an oncogenic role in colorectal cancer and that it might be a promising target for colorectal cancer therapy.
Source: Journal of International Medical Research - February 17, 2016 Category: Research Authors: Li, J., Feng, W., Chen, L., He, J. Tags: Research Reports Source Type: research

siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells.
Authors: Montazami N, Kheir Andish M, Majidi J, Yousefi M, Yousefi B, Mohamadnejad L, Shanebandi D, Estiar MA, Khaze V, Mansoori B, Baghbani E, Baradaran B Abstract One of the most challenging aspects of colon cancer therapy is rapid acquisition of multidrug resistant phenotype. The multidrug resistance gene 1 (MDR1) product, p—glycoprotein (P—gp), pump out a variety of anticancer agents from the cell, giving rise to a general drug resistance against chemotherapeutic agents. The aim of this study was to investigate the effect of a specific MDR1 small interference RNA (siRNA) on sensitivity of ox...
Source: Cellular and Molecular Biology - December 2, 2015 Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research

Role of ribophorin II in the response to anticancer drugs in gastric cancer cell lines.
Authors: Yuan TM, Liang RY, Chueh PJ, Chuang SM Abstract The identification of prognostic markers and establishing their value as therapeutic targets improves therapeutic efficacy against human cancers. Ribophorin II (RPN2) has been demonstrated to be a prognostic marker of human cancer, including breast and pancreatic cancers. The present study aimed to evaluate RPN2 expression in gastric cancer and to examine the possible correlation between RPN2 expression and the response of cells to clinical anticancer drugs, which has received little research attention at present. The gastric cancer AGS, TMC-1, SNU-1, TMK-1, ...
Source: Oncology Letters - June 4, 2015 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research